SCHEMBL5135095

SCHEMBL5135095

CCCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CCCC)Cc1ccccc1OC

nearest known ligand 0.47

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
BCHE P06276 15/20 0.47
ACHE P22303 13/20 0.47
MAOB P27338 3/20 0.43
TP53 P04637 2/20 0.42
MAPT P10636 1/20 0.42
APP P05067 1/20 0.41
GAA P10253 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CNR2 P34972 1/20 0.41
C5AR1 P21730 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5069962 0.97 BCHE (0.45) BCHEACHEMAOBAPPC5AR1
SCHEMBL5134803 0.95 BCHE (0.43) BCHEACHEMAOBAPPC5AR1
SCHEMBL5135193 0.93 BCHE (0.43) BCHEACHEMAOBTP53MAPT
SCHEMBL5136790 0.92 ALOX5 (0.42) BCHEACHEMAOBTP53MAPT
SCHEMBL5135183 0.91 PDE4B (0.39) BCHEACHEMAPTC5AR1
SCHEMBL5135916 0.91 TP53 (0.43) BCHEACHETP53GAASMN1; SMN2
SCHEMBL5136469 0.90 TP53 (0.41) BCHEACHETP53MAPTGAA
SCHEMBL5137859 0.90 ALDH1A1 (0.41) BCHEACHETP53GAASMN1; SMN2
SCHEMBL5137330 0.90 BCHE (0.43) BCHEACHEC5AR1
SCHEMBL5070121 0.89 SMN1; SMN2 (0.41) BCHEACHETP53GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed